Research Article
Vitamin D Receptor Polymorphisms Predispose to Primary Biliary Cirrhosis and Severity of the Disease in Polish Population
Table 4
Clinical and laboratory data depending on analyzed polymorphisms.
| (a) |
| | ApaI (rs7975232) | | AA (TT) | aA (GT) | aa (GG) | P
(AA versus Aa) | P
(aa versus Aa) | P
(aa versus AA) |
| | Gender (F/M) | 36/4 | 67/13 | 20/3 | 0.4 | 0.9 | 0.7 | | Cirrhosis at Lbx (N/Y) | 20/8 | 34/21 | 10/9 | 0.5 | 0.6 | 0.2 | | Advanced fibrosis stage III/IV on histology (N/Y) | 15/11 | 28/27 | 8/10 | 0.6 | 0.3 | 0.5 | | Age of diagnosis (years) | | | | 0.8 | 0.4 | 0.3 | | AST (IU/mL) | | | | 0.4 | 0.4 | 0.2 | | ALT (IU/mL) | | | | 0.2 | 0.9 | 0.3 | | AP (IU/mL) | | | | 0.2 | 0.1 | 0.02 | | GGT (IU/mL) | | | | 0.1 | 0.9 | 0.2 | | Bilirubin (mg/dL) | | | | 0.9 | 0.3 | 0.4 | | Albumin (g/dL) | | | | 0.1 | 0.9 | 0.2 | | INR | | | | 0.1 | 0.1 | 0.9 | | Cholesterol (mg/dL) | | | | 0.4 | 0.7 | 0.8 | | TG (mg/dL) | | | | 0.2 | 0.8 | 0.5 | | Sp100 Ab | 34/4 | 62/16 | 17/5 | 0.3 | 0.8 | 0.3 | | Gp210 Ab | 31/7 | 67/11 | 21/1 | 0.6 | 0.3 | 0.2 | | AMA (Y/N) | 31/9 | 68/12 | 19/4 | 0.3 | 0.7 | 0.7 |
|
|
| (b) |
| | BsmI (rs15444410) | | bb (GG) | bB (GA) | BB (AA) | P
(bb versus Bb) | P
(BB versus B) | P
(bb versus BB) |
| | Gender (F/M) | 40/8 | 66/9 | 17/3 | 0.6 | 0.7 | 0.9 | | Cirrhosis at Lbx (N/Y) | 17/22 | 38/13 | 9/3 | 0.004 | 0.9 | 0.1 | | Advanced fibrosis stage III/IV on histology (N/Y) | 15/23 | 30/20 | 6/5 | 0.1 | 0.7 | 0.5 | | Age of diagnosis (years) | | | | 0.2 | 0.1 | 0.4 | | AST (IU/mL) | | | | 0.05 | 0.9 | 0.2 | | ALT (IU/mL) | | | | 0.2 | 0.8 | 0.3 | | AP (IU/mL) | | | | 0.4 | 0.2 | 0.06 | | GGT (IU/mL) | | | | 0.2 | 0.3 | 0.7 | | Bilirubin (mg/dL) | | | | 0.5 | 0.5 | 0.8 | | Albumin (g/dL) | | | | 0.4 | 0.6 | 0.9 | | INR | | | | 0.2 | 0.4 | 0.9 | | Cholesterol (mg/dL) | | | | 0.8 | 0.4 | 0.5 | | TG (mg/dL) | | | | 0.6 | 0.2 | 0.4 | | Sp100 Ab | 35/12 | 63/10 | 15/3 | 0.1 | 0.7 | 0.5 | | Gp210 Ab | 41/6 | 62/11 | 16/2 | 0.8 | 0.9 | 0.9 | | AMA (Y/N) | 40/8 | 63/12 | 15/5 | >0.9 | 0.3 | 0.5 |
|
|
| (c) |
| | TaqI (rs731236) | | TT (TT) | Tt (TC) | Tt (CC) | P
(TT versus tT) | P
(tt versus tT) | P
(tt versus TT) |
| | Gender (F/M) | 37/9 | 69/8 | 17/3 | 0.2 | 0.7 | 0.7 | | Cirrhosis at Lbx (N/Y) | 15/9 | 40/13 | 9/3 | 0.3 | >0.9 | 0.7 | | Advanced fibrosis Stage III/IV on histology (N/Y) | 13/23 | 32/20 | 6/5 | 0.03 | 0.7 | 0.3 | | Age of diagnosis (years) | | | | 0.2 | 0.1 | 0.4 | | AST (IU/mL) | | | | 0.03 | 0.9 | 0.2 | | ALT (IU/mL) | | | | 0.2 | 0.9 | 0.3 | | AP (IU/mL) | | | | 0.4 | 0.2 | 0.06 | | GGT (IU/mL) | | | | 0.2 | 0.4 | 0.09 | | Bilirubin (mg/dL) | | | | 0.9 | 0.6 | 0.6 | | Albumin (g/dL) | | | | 0.4 | 0.6 | 0.9 | | INR | | | | 0.6 | 0.5 | 0.7 | | Cholesterol (mg/dL) | | | | 0.8 | 0.3 | 0.4 | | TG (mg/dL) | | | | 0.6 | 0.2 | 0.4 | | Sp100 Ab | 34/11 | 64/11 | 15/3 | 0.2 | 0.9 | 0.7 | | Gp210 Ab | 39/6 | 64/11 | 16/2 | 0.9 | 0.9 | 0.9 | | AMA (Y/N) | 40/6 | 62/15 | 16/4 | 0.5 | >0.9 | 0.5 |
|
|
Lbx: liver biopsy; AspAT: aspartate aminotransferase; AlAT: alanine aminotransferase; AP: alkaline phosphatase; GGT: gamma-glutamyl transferase; INR: international normalized ratio; TG: triglycerides, AMA: antimitochondrial antibodies.
|
